Use of parthenolide to inhibit cancer

Abstract

The invention provides a method comprising the use of parthenolide, including its analogs, to treat cancer or conditions characterized by abnormal angiogenesis.

1 - 13 . (canceled)  
     
     
         14 . A therapeutical method of treating a non-tumorigenic angiogenesis-dependent condition characterized by the abnormal growth of blood vessels comprising administering to a mammal afflicted with said condition an effective anti-angiogenetic amount of parthenolide.  
     
     
         15 . The method of  claim 14  wherein the mammal is a human.  
     
     
         16 . The method of  claim 15  wherein the condition is corneal neovascularization.  
     
     
         17 . The method of  claim 15  wherein the condition is hypertrophic scars and keloids.  
     
     
         18 . The method of  claim 15  wherein the condition is proliferative diabetic retinopathy.  
     
     
         19 . The method of  claim 15  wherein the condition comprises arteriovenous malformations or atherosclerosis.  
     
     
         20 . The method of  claim 15  wherein the condition comprises delayed wound healing.  
     
     
         21 . The method of  claim 14  wherein the parthenolide is administered locally.  
     
     
         22 . The method of  claim 14  wherein the parthenolide is delivered in a liquid vehicle.  
     
     
         23 . The method of  claim 14  wherein the parthenolide is delivered from a controlled release polymeric matrix.  
     
     
         24 . The method of  claim 23  wherein the parthenolide is delivered from a medical prosthesis.  
     
     
         25 . The method of  claim 24  wherein the parthenolide is delivered from a shunt, a stent or a graft.  
     
     
         26 . (canceled)